Showing results (101-110 of 185) with videos related to

Sort By:
Pageof 19
Blood Advances|September 3, 2024
Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practiceVincenzo La Mura, Vincenzo Cardinale, Raimondo De Cristofaro, et al.
Infection|December 15, 2025
Impact of HDV infection on post-transplant outcomes in patients transplanted for HBV-related liver disease: results from a multicenter cohort study in Southern ItalyGianfranca Stornaiuolo, Mariantonietta Pisaturo, Lorenzo Salmoni, et al.
Scientific Reports|March 23, 2022
COVID-19 in liver transplant recipients: incidence, hospitalization and outcome in an Italian prospective double-centre studyMaria Guarino, Valentina Cossiga, Ilaria Loperto, et al.
Blood Reviews|August 6, 2023
Awareness of individual goals, preferences, and priorities of persons with severe congenital haemophilia A for a tailored shared decision-making approach to liver-directed gene therapy. A practical guidelineGiovanni Di Minno, Gaia Spadarella, Nelson Mauro Maldonato, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|September 11, 2020
Plasma phospholipid dysregulation in patients with cystathionine-β synthase deficiencyAlessandro Di Minno, Andrea Anesi, Mattia Chiesa, et al.
Reviews on Recent Clinical Trials|December 18, 2015
Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern ItalyFilomena Morisco, Mario Masarone, Valerio Rosato, et al.
Digestive Diseases and Sciences|April 3, 2019
Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life ExperienceLuca Rinaldi, Maria Guarino, Alessandro Perrella, et al.
United European Gastroenterology Journal|March 8, 2018
Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3Filomena Morisco, Rocco Granata, Silvia Camera, et al.
Cancers|November 2, 2019
Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical PracticeEdoardo G Giannini, Andrea Aglitti, Mauro Borzio, et al.
Blood|April 21, 2026
Refined classification and phenotype-driven analysis of PIEZO1 variants in hereditary red cell and iron disordersBarbara Eleni Rosato, Roberta Marra, Stefania Martone, et al.
Pageof 19